Among the first selective and more efficacious BET inhibitors, JQ1 is able to target c-MYC in many different cancers and I-BET762 is in Phase I-II clinical trial for NUT midline carcinoma, neuroblastoma and other tumors1 (Filippakopoulos et al., 2010; Filippakopoulos and Knapp, 2014). Here, DNER is linked to cancer.